ImmunityBio, Inc. — Director's Dealing 2026

Jan 21, 2026

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ImmunityBio, Inc. (IBRX)
CIK: 0001326110
Period of Report: 2026-01-16

Reporting Person: Selecky Christobel (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2026-01-16	Common Stock	M	50000	$2.98	Acquired	50000	Direct
2026-01-16	Common Stock	S	50000	$5	Disposed	0	Direct
2026-01-20	Common Stock	M	25000	$2.98	Acquired	25000	Direct
2026-01-20	Common Stock	S	25000	$7.506	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2026-01-16	Stock Option (right to buy)	$2.98	M	50000	Disposed	2032-06-14	Common Stock (50000)	Direct
2026-01-20	Stock Option (right to buy)	$2.98	M	25000	Disposed	2032-06-14	Common Stock (25000)	Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2025.

F2: Represents the weighted average share price of an aggregate total of 25,000 shares sold in the price range of $7.50 to $7.52 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

F3: One hundred percent (100%) of the shares subject to the award vested on June 12, 2023, the date immediately preceding the 2023 annual meeting of stockholders.